TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Slides:



Advertisements
Similar presentations
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Advertisements

Clinical Research at JHP LNM – 02 October OutlineJHU- Administration Building History Influential studies- ◦ PEPI ◦ 052 Future Prospects.
Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.
Unmet need for family planning and low rates of dual method protection among men and women attending HIV care and treatment services in Kenya, Namibia.
1 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis Taha Taha 1, Johnstone Kumwenda.
Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.
Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
HIV/AIDS In Botswana. Learning objective…. Explain the impact of HIV and Aids in one African country (Botswana)
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
Effect of Early versus Delayed Initiation of Antiretroviral Therapy (ART) on Clinical Outcomes in the HPTN 052 Randomized Clinical Trial Beatriz Grinsztejn.
Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study B. Durovni1,2,
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
Beatriz Grinsztejn, MD Site Investigator Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz 6 th IAS Conference, Rome, Italy July 18, 2011 Effects of.
Johns Hopkins Center for Tuberculosis Research
Sustained Treatment as Prevention: Unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN K.H.
Health Psychology Lecture 8 Chronic Illness and AIDS.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052: Summary.
GLOBAL UNITED CHILDREN’S FOUNDATION, Inc Presents “Using Education to Contain the Spread of HIV/AIDS in Africa and Expand Treatment in Rural Communities.
Ami R. Moore, PhD Department of Sociology University of North Texas 12/01/2011.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
HIV and AIDS Epidemic: Potential Contribution from DSS sites Nyovani Madise, PhD Centre for Global Health, Population, Poverty & Policy.
PICO 4 Should antiretroviral therapy (ART) be offered to HIV-infected partners in serodiscordant couples to reduce HIV transmission to uninfected partners?
ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.
WORLD AIDS DAY Zero new HIV infections Zero discrimination Zero AIDS-related deaths.
PRECONCEPTION COUNSELING AND CARE FOR HIV-INFECTED WOMEN OF CHILDBEARING AGE.
World Health Organization | Viet Nam Country Office1 Enhancing Benefits of Early Antiretroviral Therapy Evidence, Implication and Preliminary Findings.
The HIV Care Continuum: A Tool for Driving Systematic Change to Support Better Engagement in Care Jeffrey S. Crowley Distinguished Scholar/ Program Director.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV and STI Department The case for HIV testing A presentation for the clinical team in your practice.
Washington D.C., USA, July 2012www.aids2012.org Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.
Contents - HIV global slides
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
Number of people receiving antiretroviral therapy in
“Its Different Now”: The Changing Landscape of HIV testing
Differentiated Service Delivery: Innovating for Impact
VESTED Quiz Game
On behalf of The MTN-020/ASPIRE Study Team
VESTED Quiz Game
Conclusions Background Results Acknowledgements: Methods
PrEP: A Case-by-Case Approach
HIV and the ART of Prevention
World Health Organization
HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.
Peter Godfrey-Faussett for Charlotte Watts
Contents - HIV global slides
HPTN International Scholar ( )
HIV/AIDS In Botswana.
Presentation transcript:

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

SYNOPSIS OF HPTN 052 A randomized clinical trial to evaluate the effectiveness of Antiretroviral Therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in sero-discordant couples.

STUDY OBJECTIVES Primary objective: To compare the rate of HIV infection among partners of HIV infected participants in two study arms – ARM 1: Antiretroviral therapy plus HIV primary care at time of enrolment – ARM 2: HIV primary care alone until the participant has two consecutive measurements of CD4 cell count below 250 cells/mm3 or develops an AIDS defining illness.

STUDY OBJECTIVES Evaluate the optimal time to begin antiretroviral therapy in order to reduce illness and death among people infected with HIV/AIDS.

Secondary objectives Determine long term safety of ART Characterize the pattern and rates of ART drug resistance Assess factors associated with adherence to therapy Evaluate effectiveness of couples counselling and characterize patterns of sexual behaviour in couples in both arms

Study design Phase 3, two arms, randomized controlled multicenter clinical trial Study population: HIV-1 sero-discordant couples in which the HIV infected partner is ART naive and has CD4 cell between 350 and 550 cells/mm3 Sample size: 1750 sero-discordant couples Study arms: two arms, assigned 1:1 ratio. – ARM 1: ART at enrolment plus HIV primary care – ARM 2: HIV primary care alone until participant’s CD4 cell count falls below 250 on two consecutive times or develops an AIDS defining illness

PARTICIPATING SITES Botswana: Gaborone Brazil: 2 sites Porto Alegre and Rio de Janeiro India: Chennai and PUNE Kenya: Kisumu Malawi: Blantyre and Lilongwe South Africa: Johannesburg and Soweto Thailand: Chiang Mai USA: Massachusetts Boston Zimbabwe: Harare

Results 1763 couples were enrolled from April 2005 to May % were heterosexual Mean age was 33 years Mean CD4 cell count at entry 436 cells/mm3 ( )

DSMB FINDINGS IN RELATION TO HIV TRANSMISSION 39 cases of HIV transmission among previously uninfected partners 28 transmissions were linked (i.e. The virus found in the infected partner did come from the index case) 11 transmissions were not linked (virus found in the infected partner came from someone other than the partner registered in the study) or were still being analysed 27 transmissions in the delayed arm versus 1 in the immediate arm Over 96% reduction in HIV transmission in the immediate arm HIV incidence as a whole in the study was lower than what was expected

DSMB TRANSMISSION IN RELATION TO BENEFITS OF STARTING ART EARLY 105 cases of ill health in total 65 cases in delayed arm versus 40 in immediate arm 17 cases of extrapulmonary TB in delayed arm compared to 3 in immediate arm Deaths were 10 in immediate arm versus 13 in delayed arm

ISSUES WHEN CONDUCTING 052 Difficult to enrol young people (most go for HIV testing as couples but break up immediately if results are sero-discordant Difficult to keep sero-discordant couples together. Required constant counselling Keeping to schedule of events was a huge task

ISSUES RELATED TO YOUNG PEOPLE HIV incidence highest in the age group especially in women 4.9% HIV prevalence in year age group in Malawi more in girls 6.8% compared to 3.1% in boys Trans-generational sex seems an important risk factor in girls Only 42% Overall Knowledge in the adolescent age group about HIV prevention

What to with 052 results Malawi to follow WHO recommendation to increase CD4 cell count threshold to 350 for initiating ART Preparation underway to do district-wide door to door testing for couples. Uptake for HIV testing improves significantly on home testing Increasing treatment threshold to 550 as was in 052 has both policy and resource implications Governments normally follow WHO lead.